The Latest

The Opioid Epidemic Is Fueling HIV Cluster Outbreaks -- Here's How the CDC is Responding

Epidemiologists are using a combination of molecular surveillance and tuberculosis-style contact tracing in hopes of helping local health departments curb HIV transmissions.

By Sony Salzman

TB Causes 1 in 3 HIV Deaths

In 2017, 300,000 of the total 940,000 global HIV deaths occurred among people infected by both HIV and tuberculosis (TB), according to the WHO "Global TB report 2018" launched last week.

By World Health Organization

Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment

New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.

By Simon Collins for HIV i-Base

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin

24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.

By Polly Clayden for HIV i-Base

Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin

A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.

By Polly Clayden for HIV i-Base

Significant Drug-Drug Interaction Between Dolutegravir and Isoniazid-Rifapentine

Dolutegravir (Tivicay) given with once-weekly isoniazid-rifapentine led to marked cytokine release and serious adverse events in a drug-drug interaction study.

By Polly Clayden for HIV i-Base

Twice-Daily Tenofovir Alafenamide Dose Might Overcome Interaction With Rifampicin

Twice-daily tenofovir alafenamide plus rifampicin provided similar exposures to once-daily TAF in a pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.

By Polly Clayden for HIV i-Base

Dolutegravir-Based ART in Combination With Rifampicin-Based TB Treatment Is Safe in a Small Cohort of Co-Infected Patients

Twice daily dolutegravir in combination with rifampicin was well tolerated and produced good outcomes in a small retrospective study presented at HIV Drug Therapy Glasgow 2016.

By Polly Clayden for HIV i-Base

Why Taking Vitamin D Pills Could Help the Fight Against TB and HIV

In countries such as South Africa with a high burden of TB and HIV, vitamin D could be an extremely effective and cheap weapon to include in the arsenal against the diseases.

By Anna Coussens and Allison Seeger for The Conversation

HIV and TB Link the Bronx and Tugela Ferry in a Story of Human Rights and Social Justice

With buildings leveled by arson and systematic neglect, its population crammed into debilitated and overcrowded housing without access to basic public safety and public health services, the inescapable poverty of the Bronx provided fertile ground for...

By Antigone Barton for Science Speaks